Proteolysis Targeting Chimeras (PROTACs) Based on Imatinib Induced Degradation of BCR-ABL in K562 Cells

被引：0

作者：

Li, Chuang ^{[1
]}

Zhang, Peng ^{[2
]}

Chang, Gaojie ^{[1
]}

Pan, Mingyue ^{[2
]}

Lu, Fengke ^{[1
]}

Huang, Jiahao ^{[1
]}

Wang, Yanzhi ^{[1
]}

Zhao, Qingyan ^{[1
]}

Sun, Bingxia ^{[1
]}

Cui, Yuting ^{[1
]}

Sang, Feng ^{[1
]}

机构：

[1] Shandong Univ Technol, Sch Life Sci & Med, Zibo, Shandong, Peoples R China

[2] Shenzhen Luohu Peoples Hosp, Dept Pharm, Shenzhen 518005, Guangdong, Peoples R China

来源：

CHEMISTRYSELECT | 2023年 / 8卷 / 15期

关键词：

Antitumor agents; Cytotoxicity; Kinase inhibitor; Proteolysis Targeting Chimeras; Synthesis; INHIBITOR;

D O I：

10.1002/slct.202300095

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

The proteolysis targeting chimera (PROTAC) technology is widely explored in cancer research and utilized in the treatment of various tumors and malignancies. In the design and optimization of PROTAC, linker is not only critical to the degradation activity of PROTACs, but also greatly affects the membrane permeability, metabolic stability and drug availability. In this study, fifteen new PROTACs based on Imatinib were designed, synthesized, and assessed for their anticancer activity against K562 cells. The CCK-8 assay results showed that a new PROTAC with a 2-oxoethyl linker (PROTAC 1) exhibited significant antiproliferative activity against K562 (IC50=0.62 +/- 0.02 mu M) cells. Western blot analysis showed that PROTAC 1 regulated the protein levels of BCR-ABL in a dose-dependent manner and induced degradation of BCR-ABL in a ubiquitin-proteasome-dependent manner in K562 cells. This study provides further evidence for the importance of linker selection in PROTAC design.

引用

页数：11

共 50 条

[21] Xanthohumol, a Prenylated Flavonoid from Hops, Induces Caspase-Dependent Degradation of Oncoprotein BCR-ABL in K562 Cells
Lu, Xuxiu
Geng, Jiajia
Zhang, Jinman
Miao, Jinlai
Liu, Ming
ANTIOXIDANTS, 2019, 8 (09)
[22] Transcriptional activation of Skp2 by BCR-ABL in K562 chronic myeloid leukemia cells
Chen, Jing-Yi
Wang, Ming-Chung
Hung, Wen-Chun
LEUKEMIA RESEARCH, 2009, 33 (11) : 1520 - 1524
[23] The cytotoxicity of a Grb2-SH3 inhibitor in Bcr-Abl positive K562 cells
Ye, Yun-Bin
Lin, Jian-Yin
Chen, Qianq
Liu, Fang
Chen, Hui-Jing
Li, Jie-Yu
Liu, Wang-Qing
Garbay, Christiane
Vidal, Michel
BIOCHEMICAL PHARMACOLOGY, 2008, 75 (11) : 2080 - 2091
[24] Jak2 activation by Bcr-Abl is involved in the transformation of K562 leukemia cells.
Xie, S
Wang, Y
Wu, Y
Arlinghaus, R
BLOOD, 1999, 94 (10) : 487A - 487A
[25] Reduction of Bcr-Abl function leads to erythroid differentiation of K562 cells via downregulation of ERK
Brozik, A.
Casey, N. P.
Hegedus, Cs.
Bors, A.
Kozma, A.
Andrikovics, H.
Geiszt, M.
Nemet, K.
Magocsi, M.
SIGNAL TRANSDUCTION PATHWAYS, PT A: APOPTOTIC AND EXTRACELLULAR SIGNALING, 2006, 1090 : 344 - 354
[26] BCR-ABL mediated cell cycle arrest and inhibition of apoptosis in K562 cells is not observed in MDR-1 positive K562 derivatives
Allen, PD
Reeves, BR
Kempski, HM
Ketley, NJ
Jiang, XR
Razak, K
Kelsey, SM
Newland, AC
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 1315 - 1315
[27] Nilotinib significantly induces apoptosis in imatinib resistant K562 cells with wild-type BCR-ABL, as effectively as in parental sensitive counterparts
Ekiz, Huseyin Atakan
Can, Geylani
Gunduz, Ufuk
Baran, Yusuf
HEMATOLOGY, 2010, 15 (01) : 33 - 38
[28] bcr-abl融合基因抑制K562细胞凋亡的研究
王春红
孙秉中
袁跃传
中华肿瘤杂志, 1998, (05) : 20 - 21
[29] ALTERED BCR/ABL FUSION GENE CHROMATIN IN K562 CELLS
MEARS, JG
LEIBOWITZ, D
POPENOE, D
SCHAEFERREGO, KE
CLINICAL RESEARCH, 1986, 34 (02): : A465 - A465
[30] BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): The new frontier in the treatment of Ph+ leukemias?
Cruz-Rodriguez, Nataly
Tang, Hua
Bateman, Benjamin
Tang, Weiping
Deininger, Michael
LEUKEMIA, 2024, 38 (09) : 1885 - 1893

← 1 2 3 4 5 →